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oving Preconditioning
rom Bench to Bedside*
obert A. Kloner, MD, PHD, FACC
os Angeles, California
schemic preconditioning is the one maneuver that has
onsistently been shown to reduce myocardial necrosis due
o ischemia/reperfusion injury in experimental models (1).
rief coronary occlusions of a few minutes to 10 min
ollowed by brief reperfusion periods markedly reduce the
ize of a subsequent myocardial infarction (MI) induced by
longer coronary artery occlusion followed by reperfusion.
he ability of ischemic preconditioning to reduce myocar-
ial infarct size has been observed in every species in which
he phenomenon has been tested. Ischemic preconditioning
lso confers other benefits, including a reduction in lethal
entricular arrhythmias (2). There is now ample evidence
hat ischemic preconditioning can occur in the human heart
3). Studies of isolated cardiac myocytes and human cardiac
uscle have shown that, in in vitro models that simulate
schemia/reperfusion, preconditioning protocols can protect
he compromised heart tissue. During sequential percuta-
See page 206
eous coronary artery angioplasty balloon inflations and
eflations, the evidence for ischemia in humans (chest pain,
T-segment elevation, lactate production, and regional left
entricular dysfunction) are reduced during repeat inflation/
eflation sequences compared with a first balloon inflation.
nduction of an ischemic preconditioning protocol by inter-
ittent aortic cross clamping preserves myocardial adeno-
ine triphosphate levels during coronary artery bypass graft
urgery. Patients that experience pre-infarct angina pectoris,
specially during the first 24 h before acute MI, demonstrate
maller myocardial infarcts, lower mortality, better left
entricular function, and less congestive heart failure (3–5).
econd messenger pathways have been described to explain
schemic preconditioning, and release of adenosine with
schemia/reperfusion is one of the triggers of these pathways
6). Certain adenosine agonists were shown to mimic the
rotective effects of ischemic preconditioning (6,7). Con-
ersely, adenosine antagonists have been shown to block the
ardioprotective effects of ischemic preconditioning. There
s evidence that pharmacologic agents that stimulate or
imic ischemic preconditioning pathways might do so in
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Heart Institute, Good Samaritan Hospital, Division of Cardiovascularr
edicine, Keck School of Medicine, University of Southern California, Los Angeles,
alifornia.umans. For example, in patients, adenosine was shown to
essen ischemia induced by percutaneous coronary artery
alloon inflation (8), and adenosine administered before
ardiac surgery lessened the need for high-dose inotropes
nd reduced the development of Q-wave MI (9,10). Aden-
sine infusion in high doses was shown to reduce myocar-
ial infarct size in patients with anterior wall MIs in both
he AMISTAD-I and -II (Acute Myocardial Infarction
tudy of Adenosine) studies (11,12). Of note, a recent
reliminary report from the AMISTAD-II study showed
hat, when adenosine was given along with early reperfusion
herapy (thrombolytic or percutaneous coronary interven-
ion) within 3.2 h of onset of chest pain, 1-month and
-month mortality and the combined end point of mortality
t 6 months and heart failure were significantly reduced
ompared with patients receiving placebo (13). Because
denosine was administered after the onset of myocardial
schemia, however, it is unlikely that its mechanism was
elated to true preconditioning in these studies, although it
ould have been related to postconditioning (14).
It has been 20 years since the initial description of
schemic preconditioning (1). Despite numerous studies
erifying the phenomenon both in experimental studies and
n human studies, no clinical therapy has emerged from the
henomenon that is routinely used in clinical practice.
either brief episodes of ischemia nor pharmacologic agents
hat mimic ischemia are routinely used as therapy in
atients. The study by Mangano et al. (15) in this issue of
he Journal might change this. They investigated the use of
cadesine, an adenosine-regulating agent known to increase
denosine levels within ischemic tissue. In this large, mul-
icenter study of 2,698 patients undergoing coronary artery
ypass graft surgery, patients were randomized in a double-
linded fashion to receive a 7-h infusion of acadesine versus
lacebo starting 15 min before induction of anesthesia. Use
f acadesine in this pre-ischemia fashion thus mimics the
iming of preconditioning. The primary outcome measured
n this Acadesine 1024 Trial was a 4-day assessment of
ardiac death, MI, or stroke, and this outcome was negative,
lthough there was a nonsignificant trend with a 22%
eduction in the primary combined end point favoring
cadesine. The present study assessed long-term (2-year)
urvival in patients who developed a perioperative MI.
wo-year mortality among patients who developed a peri-
perative MI was significantly lower in the acadesine-
reated group, 6.52% (3 of 46 patients), versus the placebo-
reated patients, 27.78% (15 of 54 patients). The incidence
f perioperative MI was 22% lower in the acadesine-treated
roup, although this did not reach statistical significance.
hus, the present study suggests that pretreatment with
cadesine—a potentially preconditioning mimetic agent—
mproves long-term survival in patients who develop a
erioperative MI.
The exact mechanism by which acadesine had this benefitemains to be determined. The fact that there was a trend
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Editorial Comment July 4, 2006:215–6or acadesine to reduce the incidence of perioperative MI
uggests that it might have an anti-necrosis effect possibly
y stimulating preconditioning pathways via adenosine.
hether myocardial infarct size was truly reduced by
cadesine remains to be determined from this study. Other
ssues that remain to be resolved is whether acadesine
mparted some anti-arrhythmic effect in these patients or
hether it improved long-term global and regional left
entricular function.
In summary, the present study by Mangano et al. (15)
rovides original data that suggest that a preconditioning
imetic agent can be used to improve survival of patients
ho develop a perioperative MI associated with a coronary
rtery bypass surgery. The adenosine-regulating agent
cadesine reduced mortality by 4.3-fold in these patients,
nd the benefit was long-lasting. This study successfully
oves forward the concept of preconditioning as a therapy
rom bench to bedside.
eprint requests and correspondence: Dr. Robert A. Kloner,
eart Institute, Good Samaritan Hospital, 1225 Wilshire Boule-
ard, Los Angeles, California 90017. E-mail: rkloner@goodsam.
rg.
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